Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Imatinib therapy, which targets the oncogene product BCR-ABL, has transformed chronic myeloid leukemia (CML) from a life-threatening disease into a chronic condition. Most patients, however, harbor residual leukemia cells, and disease recurrence usually occurs when imatinib is discontinued. Although various mechanisms to explain leukemia cell persistence have been proposed, the critical question from a therapeutic standpoint--whether disease persistence is BCR-ABL dependent or independent--has not been answered. Here, we report that human CML stem cells do not depend on BCR-ABL activity for survival and are thus not eliminated by imatinib therapy. Imatinib inhibited BCR-ABL activity to the same degree in all stem (CD34+CD38-, CD133+) and progenitor (CD34+CD38+) cells and in quiescent and cycling progenitors from newly diagnosed CML patients. Although short-term in vitro imatinib treatment reduced the expansion of CML stem/progenitors, cytokine support permitted growth and survival in the absence of BCR-ABL activity that was comparable to that of normal stem/progenitor counterparts. Our findings suggest that primitive CML cells are not oncogene addicted and that therapies that biochemically target BCR-ABL will not eliminate CML stem cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Even potent TKIs are unable to eradicate CML-LSCs,6,7 which are the main culprit of disease relapse upon TKI discontinuation.”
From Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia (2024) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Ki-67 protein: From the known and the unknown
Scholzen, T., & Gerdes, J. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200003)182:3<311::aid-jcp1>3.0.co;2-9 · Cited by 4,646 · cited 1×
“To clarify this question, we analyzed BCR-ABL activity in imatinib-treated quiescent CML cells using Ki-67 negativity as a marker of quiescence (37).”
MethodFive-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488 · cited 3×
“Newly diagnosed patients with chronic phase CML have an almost 90% chance of being alive at 60 months after diagnosis (2).”
BackgroundSelf-citationClinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Zhou, S., Schuetz, J. D., Bunting, K. D., Colapietro, A.-M., Sampath, J., Morris, J. J., Lagutina, I., Grosveld, G. C., Osawa, M., Nakauchi, H., et al. (2001) · Nature Medicine · doi:10.1038/nm0901-1028 · Cited by 2,280 · cited 2×
“Enhanced expression of the drug efflux pumps breast cancer resistance protein (10) and P-glycoprotein (11) in CML stem cells may reduce sensitivity to imatinib by lowering intracellular imatinib concentrations (12–15).”
BackgroundAC133, a Novel Marker for Human Hematopoietic Stem and Progenitor Cells
Yin, A. H., Miraglia, S., Zanjani, E. D., Almeida-Porada, G., Ogawa, M., Leary, A. G., Olweus, J., Kearney, J., & Buck, D. W. (1997) · Blood · doi:10.1182/blood.v90.12.5002 · Cited by 1,822
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,796
The molecular biology of chronic myeloid leukemia
Deininger, M. W. N., Goldman, J. M., & Melo, J. V. (2000) · Blood · doi:10.1182/blood.v96.10.3343 · Cited by 1,667 · cited 2×
“Introduction Chronic myeloid leukemia (CML) originates in a HSC with the reciprocal translocation t(9;22) (1).”
BackgroundSelf-citationCharacterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.007 · Cited by 1,492 · cited 1×
“Introduction Chronic myeloid leukemia (CML) originates in a HSC with the reciprocal translocation t(9;22) (1).”
BackgroundHughes, T. P., Kaeda, J., Branford, S., Rudzki, Z., Hochhaus, A., Hensley, M. L., Gathmann, I., Bolton, A. E., van Hoomissen, I. C., Goldman, J. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030513 · Cited by 1,218 · cited 4×
“Those whose disease is undetectable by RT-PCR usually experience recurrence of active leukemia when imatinib therapy is discontinued (4, 5), which indicates that leukemic cells persist in most patients even when the disease burden is reduced below detectable limits.”
BackgroundInfluentialGraham, S. M., Jørgensen, H. G., Allan, E., Pearson, C., Alcorn, M. J., Richmond, L., & Holyoake, T. L. (2002) · Blood · doi:10.1182/blood.v99.1.319 · Cited by 1,181 · cited 6×
“In accord with previous reports (19), we observed that primitive noncycling BCR-ABL–positive cells”
BackgroundResultInfluential
Cited by
Items 701–799 of 799
The role of cytokines in governing the expansion of the T315I mutation in chronic myeloid leukaemia.
Lee, O.-L. (2014) · Adelaide Research & Scholarship (AR&S) (University of Adelaide)
Biologie moléculaire de la leucémie myéloïde chronique : dernières avancées
Chomel, J. (2017) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(17)30162-4 · Cited by 5
Schmitt, K., Isfort, S., Koschmieder, S., & Brümmendorf, T. H. (2015) · best practice onkologie · doi:10.1007/s11654-015-0245-y
oncoprotein BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic
Deininger, M. W., Firpo, E. J., Cortes, J. E., McWeeney, S. K., O’Hare, T., Roberts, J. M., Fleischman, G., Duquesnes, N., Eide, C. A., Vasudevan, K. B., et al. (2014)
Self-citationEnhancement of death receptor-mediated apoptosis in multiple myeloma cells
Arhoma, A. A. (2017) · Sheffield Hallam University · doi:10.7190/shu-thesis-00026 · Cited by 1
“21 (adapted from Al-Hajj et al., 2003; Bae et al., 2010; Bhatia et al., 1997; Brychtova et al., 2007; Collins et al., 2005; Corti et al., 2006; Corbin et al., 2011; Dean ., 2009; Du et al., 2008; Ginestier et al., 2007; Hart et al., 2005; Huang et al., 2009; Jeter et al., 2011; Johansson et al.,…”
Stem Cell Transplantation for Treatment of Malignancy
Bachegowda, L., & Champlin, R. E. (2018) · Wiley eBooks · doi:10.1002/9781118684535.ch15
Ruiz, M. S., Sánchez, M. B., Gutiérrez, L., Koile, D., Yankilevich, P., Mosqueira, C., Cranco, S., Custidiano, M. D. R., Freitas, J., Foncuberta, C., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24749
Chronic myeloid leukemia: the possibility of a cure
Sobrinho-Simões, M. A., Ross, D. M., & Melo, J. V. (2013) · doi:10.2217/ebo.13.131
New direction of PAI-1 inhibitor development: Clinical application to cancer treatment
Dan, T., Uchida, W., HIRATSUKA, H., Oshima, Y., & Miyata, T. (2018) · Japanese Journal of Thrombosis and Hemostasis · doi:10.2491/jjsth.29.487
Ribeiro, R. S. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2018.tde-25042018-161724
Halvarsson, C. (2018) · Linköping University medical dissertations · doi:10.3384/diss.diva-152129 · Cited by 1
Abrishami, M. (2018) · HARVEST (University of Saskatchewan)
Berger, M. G., & Bourgne, C. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-14366-4_10
Liu, Y., Zhang, Y., Han, W., Zhang, X., Huang, X., & Xu, L. (2019) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2019.08.017
“[24] Corbin AS, Agarwal A, Loriaux M, et al.”
BackgroundDie CML und das Problem der Stammzellpersistenz
Schemionek, M. (2020) · InFo Hämatologie + Onkologie · doi:10.1007/s15004-020-8107-3
“Begründet liegt diese Persistenz – im folgenden auch Resistenz genannt – in der Fähigkeit der LSC, auch nach Inhibition von BCR-ABL1 weiter zu überleben – sozusagen „Onkogen-unabhängig“ [6, 7].”
BackgroundWardhani, S. O., Susianti, H., Rahayu, P., & Yueniwati, Y. (2020) · Clinical Cancer Drugs · doi:10.2174/2212697x07999200824115628
KML VE KML LÖSEMİK KÖK HÜCRESİ ARASINDA MİKRORNA EKSPRESYON DEĞİŞİMLERİNİN DEĞERLENDİRİLMESİ
Pehlivan, M., Soyöz, M., Çöven, H. İ. K., Çerçi, B., Ayna, T. K., Ateş, H., Yüce, Z., & Sercan, H. O. (2019) · SDÜ Tıp Fakültesi Dergisi · doi:10.17343/sdutfd.624530
Santoro, M., Mancuso, S., Tolomeo, M., Pipitone, R. M., Grimaudo, S., & Siragusa, S. M. (2021) · Preprints.org · doi:10.20944/preprints202110.0171.v1
“This was evidenced by both in vitro and in vivo trials concluding that CML LSCs were not “oncogene-addicted” and that targeting of BCR-ABL1 kinase activity alone would not eliminate them [17,18].”
BackgroundWaking up CML leukemia stem cells for the kill
Lv, K., & Tong, W. (2022) · Blood · doi:10.1182/blood.2021014629
Smith, B. D., & Webster, J. A. (2017) · Wiley eBooks · doi:10.1002/9781119196235.ch50
Krause, D. S. (2021) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.737157730.793583289
Krause, D. S. (2021) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.733947391.793583300
Faculty Opinions recommendation of Chronic myeloid leukemia stem cells.
Krause, D. S. (2021) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735836791.793583291
Krause, D. S. (2021) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.737196975.793583299
Jiang, X., & Rothe, K. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.733947391.793554355
Boni, C., Bonifacio, M., Vezzalini, M., Scaffidi, L., Tomasello, L., Parker, L. L., Boscarino, D., Paladin, D., Krampera, M., & Sorio, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.904510
EXABS-156-CML Beyond TKI Therapy in CML
Freeman-Mills, L., & Copland, M. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/s2152-2650(22)00663-2
The role of calcium ions in the leukemic bone marrow microenvironment
Pereira, R. S. (2022) · Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) · doi:10.21248/gups.68681
Traitement par imatinib de la leucémie myéloïde chronique : 20 ans après
Réa, D. (2023) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2023.04.005
Benjamin, E. S. B., Babu, D., Joshi, G., Rajamani, B. M., Nandy, K., Rani, S., Anandan, S., Premkumar, C., Maddali, M., Abraham, A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.01.543015
“2023 Feb 1 [cited 421 2023 Apr 11];12(4):598.”
BackgroundInfluentialBasic Hematopoiesis and Leukemia Stem Cells
Hwang, W. Y. K., Bari, S., Ng, L. G., Itahana, K., Li, S., Koh, J. Y. P., & Than, H. (2023) · Springer eBooks · doi:10.1007/978-981-99-3810-0_1
BCR : ABL1-induced leukemogenesis : impacts of miR-495 and circadian clock
Rittavee, Y. (2022) · theses.fr (ABES) · doi:10.70675/f79e1c03z076cz446dz86a1z5d8571c9c016 · Cited by 1
Warfvinge, R., Ulfsson, L. G., Dhapola, P., Safi, F., Sommarin, M. N. E., Soneji, S., Hjorth‐Hansen, H., Mustjoki, S. M., Richter, J., Thakur, R. K., et al. (2024) · eLife · doi:10.7554/elife.92074.2
Wijaya, I., Bashari, M. H., Reniarti, L., Rahmawati, A., & Roesli, R. M. A. (2024) · Disease Markers · doi:10.1155/2024/2906566
“Therefore, tyrosine kinase inhibitors, such as imatinib, have been a gold standard of CML treatment [1, 7 – 9 , Patients in this study were diagnosed as having Ph + CML in the chronic phase and received imatinib with a dose of 400 mg per day.”
BackgroundMethodKhan, M. S. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.06.658261
“A significant proportion of CML patients develop resistance to TKIs, primarily due to the inability of these drugs to eradicate leukemia stem cells (LSCs), which are responsible for disease propagation and regeneration [7, 9, 16].”
Desterke, C., Griscelli, A. B., & Turhan, A. G. (2025) · Bioengineering · doi:10.3390/bioengineering12080830
Gullaksen, S., Brevik, M., Craig, E., Hellesøy, M., Sefland, Ø., Olsson‐Strömberg, U., Stentoft, J., Richter, J., Gedde‐Dahl, T., Tibshirani, R. J., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1101/2025.11.10.687542
Tsukahara, F., Kaji, K., & Maru, Y. (2025) · Leukemia Research · doi:10.1016/j.leukres.2025.108146
Rozic, G. (2025) · American Journal of Cancer Research · doi:10.62347/nlyq6344
Grover, P. (2015) · D-Scholarship@Pitt (University of Pittsburgh)
Additional file 13 of Compact CRISPR genetic screens enabled by improved guide RNA library cloning
Heo, S.-J., Enriquez, L. D., Federman, S., Chang, A. Y., Mace, R., Shevade, K., Nguyen, P., Litterman, A. J., Shafer, S., Przybyla, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26669550
Additional file 2 of Compact CRISPR genetic screens enabled by improved guide RNA library cloning
Heo, S.-J., Enriquez, L. D., Federman, S., Chang, A. Y., Mace, R., Shevade, K., Nguyen, P., Litterman, A. J., Shafer, S., Przybyla, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25034490
Busch, C., Mulholland, T., Zagnoni, M., Dalby, M. J., Berry, C. C., & Wheadon, H. (2024) · Figshare · doi:10.6084/m9.figshare.26646861
Additional file 3 of Compact CRISPR genetic screens enabled by improved guide RNA library cloning
Heo, S.-J., Enriquez, L. D., Federman, S., Chang, A. Y., Mace, R., Shevade, K., Nguyen, P., Litterman, A. J., Shafer, S., Przybyla, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26669520
Additional file 4 of Compact CRISPR genetic screens enabled by improved guide RNA library cloning
Heo, S.-J., Enriquez, L. D., Federman, S., Chang, A. Y., Mace, R., Shevade, K., Nguyen, P., Litterman, A. J., Shafer, S., Przybyla, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26669523
Additional file 7 of Compact CRISPR genetic screens enabled by improved guide RNA library cloning
Heo, S.-J., Enriquez, L. D., Federman, S., Chang, A. Y., Mace, R., Shevade, K., Nguyen, P., Litterman, A. J., Shafer, S., Przybyla, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26669532
Additional file 10 of Compact CRISPR genetic screens enabled by improved guide RNA library cloning
Heo, S.-J., Enriquez, L. D., Federman, S., Chang, A. Y., Mace, R., Shevade, K., Nguyen, P., Litterman, A. J., Shafer, S., Przybyla, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26669541
Additional file 12 of Compact CRISPR genetic screens enabled by improved guide RNA library cloning
Heo, S.-J., Enriquez, L. D., Federman, S., Chang, A. Y., Mace, R., Shevade, K., Nguyen, P., Litterman, A. J., Shafer, S., Przybyla, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26669547
Additional file 14 of Compact CRISPR genetic screens enabled by improved guide RNA library cloning
Heo, S.-J., Enriquez, L. D., Federman, S., Chang, A. Y., Mace, R., Shevade, K., Nguyen, P., Litterman, A. J., Shafer, S., Przybyla, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26669553
Busch, C., Mulholland, T., Zagnoni, M., Dalby, M. J., Berry, C. C., & Wheadon, H. (2023) · Figshare · doi:10.6084/m9.figshare.26646864
Additional file 9 of Compact CRISPR genetic screens enabled by improved guide RNA library cloning
Heo, S.-J., Enriquez, L. D., Federman, S., Chang, A. Y., Mace, R., Shevade, K., Nguyen, P., Litterman, A. J., Shafer, S., Przybyla, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26669538
Additional file 8 of Compact CRISPR genetic screens enabled by improved guide RNA library cloning
Heo, S.-J., Enriquez, L. D., Federman, S., Chang, A. Y., Mace, R., Shevade, K., Nguyen, P., Litterman, A. J., Shafer, S., Przybyla, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26669535
Busch, C., Mulholland, T., Zagnoni, M., Dalby, M. J., Berry, C. C., & Wheadon, H. (2024) · Figshare · doi:10.6084/m9.figshare.26646858
Additional file 5 of Compact CRISPR genetic screens enabled by improved guide RNA library cloning
Heo, S.-J., Enriquez, L. D., Federman, S., Chang, A. Y., Mace, R., Shevade, K., Nguyen, P., Litterman, A. J., Shafer, S., Przybyla, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26669526
Additional file 11 of Compact CRISPR genetic screens enabled by improved guide RNA library cloning
Heo, S.-J., Enriquez, L. D., Federman, S., Chang, A. Y., Mace, R., Shevade, K., Nguyen, P., Litterman, A. J., Shafer, S., Przybyla, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26669544
Additional file 15 of Compact CRISPR genetic screens enabled by improved guide RNA library cloning
Heo, S.-J., Enriquez, L. D., Federman, S., Chang, A. Y., Mace, R., Shevade, K., Nguyen, P., Litterman, A. J., Shafer, S., Przybyla, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26669556
Additional file 1 of Compact CRISPR genetic screens enabled by improved guide RNA library cloning
Heo, S.-J., Enriquez, L. D., Federman, S., Chang, A. Y., Mace, R., Shevade, K., Nguyen, P., Litterman, A. J., Shafer, S., Przybyla, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25034376
Additional file 6 of Compact CRISPR genetic screens enabled by improved guide RNA library cloning
Heo, S.-J., Enriquez, L. D., Federman, S., Chang, A. Y., Mace, R., Shevade, K., Nguyen, P., Litterman, A. J., Shafer, S., Przybyla, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26669529
Ruzzolini, J. (2021) · Florence Research (University of Florence)
Vijay, P. (2018) · eCommons (Cornell University)
Tasneem, A., Singh, M., Bairagya, H. R., & Dohare, R. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.111342
Targeting Cathepsin-G to Overcome Leukemic Stem Cell Persistence in Chronic MyeloidPreprint
Benjamin, E. S. B., Illangeswaran, R. S. S., Rajamani, B. M., Mohan, A., Rane, M. A., Abraham, A., Mathews, V., Velayudhan, S. R., & Balasubramanian, P. (2026) · Research Square · doi:10.21203/rs.3.rs-8580579/v1
Massimino, M., Tirrò, E., Romano, C., Stella, S., Tomarchio, C., Vitale, S. R., Manzella, L., Raimondo, F. D., Stagno, F., & Vigneri, P. G. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1780054 · Cited by 1
Etude des rétrotransposons LINE-1 dans la leucémie myéloïde chronique
Josselin, M. (2012) · theses.fr (ABES) · doi:10.70675/bc47fd06zd375z4cbcz8dbez5fac13e7c5ae
Airiau, K. (2012) · theses.fr (ABES) · doi:10.70675/bf87e163z09f5z4e4bzb5b2z45c3aa05c104 · Cited by 1
Anti-tumoral properties of EAPB0503, a new imidazoquinoxaline compound, in Chronic Myeloid Leukemia
Saliba, J. L. (2013) · theses.fr (ABES) · doi:10.70675/1e4ee9e0z4087z42e1zb180zf56bd6cbe37d
Fonctions oncogéniques de STAT5 : rôle dans la régulation du métabolisme oxydatif
Bourgeais, J. (2015) · theses.fr (ABES) · doi:10.70675/642a7bdcz3eb5z47fcza4fez4dd048c937e2
Identification de microARN impliqués dans la leucémogenèse
Espadinha, A.-S. (2016) · theses.fr (ABES) · doi:10.70675/e198eeb7zc6e1z4590z9be9z3ad38c33c75d
Rôle de la signalisation calcique dans la leucémie myéloïde chronique
Cabanas, H. (2016) · theses.fr (ABES) · doi:10.70675/c181bc1bz921ez4646zb959zc5a09cbd0a47
Grockowiak, É. (2017) · theses.fr (ABES) · doi:10.70675/600cdac6za637z42abz900fzf78b400f9638
Etude des effecteurs de la voie Ca2+/Calmoduline dans les leucémies aiguës lymphoblastiques T
Catherinet, C. (2017) · theses.fr (ABES) · doi:10.70675/aa90c6a6z8815z4b8bz81ccz3038ffc2614d
Transcriptional control induced by bcr-abl and its role in leukemic stem cell heterogeneity.
Pagliaro, S. (2020) · theses.fr (ABES) · doi:10.70675/7d2fa3b7zf557z42d3za768zf4948173ee14
Muselli, F. (2020) · theses.fr (ABES) · doi:10.70675/96bf921az71baz4a4dz8d53z2717fadd83a6 · Cited by 1
Gupta, S., Nigam, N., Verma, S. K., Trivedi, R., Venkatesh, V., & Kumar, D. (2026) · ACS Omega · doi:10.1021/acsomega.5c13117
Martin, J., Cliquot, J., Kim, R., Mathis, S., Cayuela, J., Passet, M., Gaillard, B., Himberlin, C., Baruchel, A., Itzykson, R., et al. (2026) · HemaSphere · doi:10.1002/hem3.70372
“Noteworthy, no TKI resistance mutations were detected despite multiple prior TKI exposures, suggesting that these pre ‐ LSCs are largely quiescent and do not strictly depend on BCR::ABL1 signaling for their survival, as described in CML. 16,17 By contrast with CML, however, the pre ‐ LSC reservoir in these cases appea…”
Measurable Residual Disease and the Unresolved Biology of Leukemic Stem Cells
Bhartiya, D., Jha, N., Dutta, S., Tripathi, A., & Tripathi, A. (2026) · Stem Cell Reviews and Reports · doi:10.1007/s12015-026-11195-5
Longo, E., Markovic, U., Stella, S., Antolino, A., Massimino, M., Fazio, M., Raimondo, F. D., Allegra, A., & Stagno, F. (2026) · Annals of Hematology · doi:10.1007/s00277-026-07233-4
Pinnelli, V. B. K., THANGACHI, S. B., Anjanappa, J. C., Kandi, V., Murthuza, A. A., & CHENOLY, S. K. (2026) · Eurasian Journal of Medicine and Oncology · doi:10.36922/ejmo026270318
SURESHKUMAR, V., Ramalingam, K., & Balasubramanian, A. (2026) · Journal of Applied Pharmaceutical Science · doi:10.1177/22313354261472053
“22,23 SRC-family kinase activity contributes to this survival architecture by sustaining downstream STAT5, AKT, and MAPK signaling, and increased SRC activity has been linked to imatinib resistance even in the absence of ABL1 kinase-domain mutations.”
CD7 CAR-T cells eliminate chronic myeloid leukemia stem cells specifically and effectively
Zhang, W., Wang, H., Tang, L., Kong, Y., You, Y., Zhu, X., & Wang, H. (2026) · Hematology · doi:10.1080/16078454.2026.2719241
Yen, R., Wu, A., Chen, M., Yue, L., Lizardo, M. M., Hughes, C. S., Leung, J., Liu, Y., Forrest, D. L., Sorensen, P. H. B., et al. (2026) · Leukemia · doi:10.1038/s41375-026-03157-0
Sun, Z., Liu, S., Ning, Y., Dang, J., Hao, Z., Wang, X., Qiao, B., Jin, Q., Dong, K., Yan, C., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.2005945
Vidhyadharan, R. T., Illangeswaran, R. S. S., Rajamani, B. M., Das, S., Mahalingam, G., Marepally, S. K., Kulkarni, U. P., Mathews, V., Velayudhan, S. R., & Balasubramanian, P. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.2005587
Challenges of Treatment: Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia
Hughes, T. P., Ross, D. M., & Melo, J. V. (2014) · Springer eBooks · doi:10.1007/978-3-319-08350-6_5
Barraco, M. (2014) · AMS Dottorato Institutional Doctoral Theses Repository (University of Bologna) · doi:10.6092/unibo/amsdottorato/6211
“Bosutinib (formerly SKI-606) is a new second-generation oral, dual Src/Abl TKI that has been shown to be more efficient than imatinib against CML cell lines (Puttini et al., 2006).”
BackgroundInfluentialProteomic analysis of leukaemogenic protein tyrosine kinase action
Griaud, F. (2012) · Research Explorer (The University of Manchester)
Metadata
- Authors
- Corbin, A. S., Agarwal, A., Loriaux, M., Cortes, J., Deininger, M. W., & Druker, B. J.
- Affiliations
- Howard Hughes Medical Institute (US)
- Oregon Health & Science University (US)
- Venue
- Journal of Clinical Investigation
- Published
- 2011-01-04
- Volume
- 121
- Issue
- 1
- Pages
- 396-409
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3007128
- OpenAlex
- W2122224021
- Cited by
- 765
- References
- 47
- Citations by year
- 2026: 13 · 2025: 20 · 2024: 32 · 2023: 34 · 2022: 43 · 2021: 48 · 2020: 57 · 2019: 51 · 2018: 47 · 2017: 66 · 2016: 53 · 2015: 51 · 2014: 67 · 2013: 76 · 2012: 66
- FWCI
- 36.63
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Defense
- T.J. Martell Foundation
- Leukemia and Lymphoma Society
- National Heart, Lung, and Blood Institute (R01HL082978, HL082978-01)
- National Cancer Institute (R37CA065823)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- chronic myeloid leukemia, imatinib, BCR-ABL, leukemia stem cells, disease persistence, drug resistance, stem cell survival, CD34+CD38- cells, CD133, progenitor cells, oncogene addiction
- MeSH terms
- Imatinib Mesylate, Antineoplastic Agents, Benzamides, Cell Survival, Humans, Models, Biological, Piperazines, Pyrimidines, Neoplastic Stem Cells, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Fusion Proteins, bcr-abl, Cytokines, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, Cell Proliferation, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.